- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05619835
A Usability Study of a Tele-health Service for Patients With Peripheral Arterial Disease.
The aim of the study is to analyze the applicability (usability) of a tele-health service as part of a potential disease management program for patients with peripheral arterial disease.
The following investigations will be conducted as part of the usability study. In the context of a tele-health service, knowledge, physical condition (including walking distance) will be documented during face-to-face and televisits, dislocated supervised gait training and education will be provided, and satisfaction with the tele-health service will be evaluated.
Study Overview
Status
Conditions
Detailed Description
Disease management programs (DMPs) are one of the methods used to optimize the care of patients with chronic diseases. DMPs are coordinated health care measures for patient populations with diseases in which active patient participation in treatment can lead to substantial effects. Specific treatment regimens, based on evidence-based treatment guidelines and structured patient information, are predominantly aimed at preventing disease exacerbations and complications. The World Health Organization (WHO) also recommends, among other things, forcing patient adherence through structured information and patient empowerment strategies to establish participatory treatment.
Peripheral arterial disease (PAD) causes oxygen and nutrient deprivation of tissues through narrowing of arterial vessels in the extremities. The cause of PAD is arteriosclerosis. The course of the disease begins asymptomatically and manifests itself over time with pain and cramps predominantly in the muscles of the lower extremity. The pain symptoms usually occur initially during physical exertion, and later at rest. As PAD progresses, chronic ulceration and necrosis occur.
Professional societies such as the European Society of Cardiology (ESC) and the European Society of Vascular Medicine (ESVM) regularly publish guidelines for the diagnosis and treatment of PAD. Therapy of PAD consists of drug therapy for the purpose of cardiovascular risk reduction (lipid and blood pressure lowering drugs and anticoagulant drugs as well as therapy of diabetes mellitus). Another aspect in the event of disease progression is interventional angioplasty, in which the affected constriction in the leg arteries is dilated and, if necessary, treated with stents. Another important pillar is also structured and supervised gait training and, in general, an improvement in lifestyle with cessation of nicotine abuse and a healthy diet.
In particular, structured gait training, which should be performed at least three times a week for 30 to 60 minutes, is strongly recommended in the current ESVM and ESV guidelines. Studies showed that structured gait training can increase walking distance by 200% in 12 weeks in patients with claudication. Daily individual interval training of 60 minutes with 5- to 15-minute intervals also proved effective in increasing walking distance. This is to overcome the pain threshold of claudication while walking. Furthermore, evidence showed that gait training may be equivalent to endovascular interventions in terms of long-term outcomes.
The aim of this study is to analyze the applicability (usability) of a telehealth service as part of a potential disease management program for patients with peripheral arterial disease.
A prospective monocentric pilot study will be conducted at the clinical department of angiology.
The study duration per participant is 90 (±14) days and is divided into 2 observation phases. In phase 1, there will be supervision by a certified nurse and the telehealth service app, and in phase 2, there will be only singular use of the app without contact by the certified nurse.
The Declaration of Helsinki (as amended from time to time) and the guidelines of "Good Clinical Practice" were taken into account in the conduct and also the planning of the study.
Furthermore, the framework guideline for the "IT infrastructure in the application of telemonitoring" was used for the planning of the study.
According to the manufacturer's manuals, the pedometers AS80/AS97/AS99 from the company Beurer are not medical devices. The app serves as a diary for patients and is not a Clinical Decision Support System. The "User's Manual PAD Stepping" is included with the study material.
Reference Projects:
The DMS app system is also already being used in routine care in the "Herzmobil" project in Styria and Tyrol. Here, patients with chronic heart failure are cared for.
The use of the DMS app is currently also being used in two other studies. These are observational studies that are not subject to the Medical Devices Act. Both projects have a positive ethics vote and are listed under the following titles:
- Telemedical follow-up of hospitalized patients with coronavirus disease-2019 (COVID-19) DRKS ID of the study: DRKS00022244.
- Building a training database of voice data recordings and body weight trajectories in hemodialysis patients for algorithm development.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Steiermark
-
Graz, Steiermark, Austria, 8036
- Medical University of Graz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented diagnosis of "peripheral arterial occlusive disease" in, IIa and IIb (according to Fontaine).
- Age between 18 and 80 years
- Written informed consent
- Smartphone with Android operating system
- Understanding of how to use the tele-health service
Exclusion Criteria:
- Patients with PAD stages I, III and IV (according to Fontaine)
- Lack of compliance
- Smartphone with non-Android operating system or incompatible software
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction with the telehealth service.
Time Frame: At time point visit 3, which is 12 weeks after baseline
|
Study participants will undergo guided interviews measuring patient satisfaction with telehealth service.
|
At time point visit 3, which is 12 weeks after baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients, who would be satisfied with the telehealth service if telephone calls would not be provided by a nurse during the programme
Time Frame: At time point visit 3, which is 12 weeks after baseline
|
Yes/No
|
At time point visit 3, which is 12 weeks after baseline
|
|
Change of walking distances in the 6 minute walk test determined by the certified nursing staff in response to the telehealth service.
Time Frame: From baseline to visit 3, which is 12 weeks after baseline
|
Walking distances in the 6 minute walk test will be determined by the certified nursing staff.
|
From baseline to visit 3, which is 12 weeks after baseline
|
|
Change of subjective limitations in the activities of daily living.
Time Frame: From baseline to visit 3, which is 12 weeks after baseline
|
Study participants will undergo a questionaire (SF36) measuring subjective limitations in the activities of daily living.
|
From baseline to visit 3, which is 12 weeks after baseline
|
|
Change of knowledge about peripheral arterial disease.
Time Frame: From baseline to visit 3, which is 12 weeks after baseline
|
Study participants will undergo a questionaire measuring knowledge about peripheral arterial disease before and 12 weeks after a structured education.
|
From baseline to visit 3, which is 12 weeks after baseline
|
|
Total number of performed 6 minute walk tests during the telehealth service.
Time Frame: At time point visit 3, which is 12 weeks after baseline
|
Study participants will perform 6 minute walk tests independently using the App during the telehealth service.
|
At time point visit 3, which is 12 weeks after baseline
|
|
Differences of the walking distance in the same 6 minute walk test determined by the nursing staff compared the App.
Time Frame: At baseline and at visit 3, which is 12 weeks after baseline
|
Walking distances in the 6 minute walk test will be determined by the certified nursing staff as well as by the App.
|
At baseline and at visit 3, which is 12 weeks after baseline
|
|
Average steps per day during the telehealth service.
Time Frame: From baseline to visit 3, which is 12 weeks after baseline
|
Descriptive
|
From baseline to visit 3, which is 12 weeks after baseline
|
|
Change of summed seconds in the "Time up and Go Test".
Time Frame: From baseline to visit 3, which is 12 weeks after baseline
|
The "Time up and Go Test" will be performed by an installed automatic measure system and will be observed by the certified nursing staff.
The patient has to stand up from a chair and walk three meter straight.
The time needed for this procedure will be measured exactly by a sensor supported measure system.
|
From baseline to visit 3, which is 12 weeks after baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1566-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
Louisiana State University Health Sciences Center...Not yet recruitingPeripheral Arterial Disease(PAD)United States
-
BayerCompleted
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany